PharmaCyte Biotech (PMCB) Enterprise Value (2016 - 2026)
PharmaCyte Biotech (PMCB) has disclosed Enterprise Value for 15 consecutive years, with -$20.5 million as the latest value for Q1 2026.
- Quarterly Enterprise Value fell 22.57% to -$20.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$20.5 million through Jan 2026, down 22.57% year-over-year, with the annual reading at -$15.5 million for FY2025, 69.03% up from the prior year.
- Enterprise Value for Q1 2026 was -$20.5 million at PharmaCyte Biotech, down from -$15.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$13.4 million in Q3 2025, with the low at -$86.6 million in Q1 2022.
- Average Enterprise Value over 5 years is -$51.0 million, with a median of -$61.2 million recorded in 2024.
- The sharpest move saw Enterprise Value tumbled 8471.89% in 2022, then surged 72.63% in 2025.
- Over 5 years, Enterprise Value stood at -$77.0 million in 2022, then increased by 4.6% to -$73.4 million in 2023, then soared by 71.62% to -$20.8 million in 2024, then increased by 25.11% to -$15.6 million in 2025, then tumbled by 31.59% to -$20.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$20.5 million, -$15.6 million, and -$13.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.